Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
Gildan Activewear Q1 2026 Earnings Call - Hanes Integration Drives Record Sales, Synergy Targets Intact
Gildan Activewear reported a massive 64% year-over-year jump in Q1 2026 sales to nearly $1.2 billion, a direct result of fully consolidating the HanesBrands acquisition. While the top line surged, adj...
- Record Q1 2026 sales from continuing operations reached nearly $1.2 billion, up 64% year-over-year, driven almost entirely by the full consolidation of the HanesBrands acquisition.
- Adjusted diluted EPS from continuing operations fell to $0.43, down 27.1% from $0.59 in Q1 2025, reflecting integration costs, higher SG&A, and a $106 million inventory fair value step-up charge.
- Management reaffirmed its objective to capture approximately $100 million in run-rate cost synergies in 2026, with full integration of Hanes production into Gildan’s low-cost facilities progressing as planned.
- +7 more takeaways
WISeKey International Holding Full Year 2025 Earnings Call - Cash Hoard and Quantum Pipeline Set 2026 Conversion
WISeKey International Holding reported a pivotal financial year, with 2025 revenue surging 62% year-over-year to CHF 19.3 million, driven largely by a 66% growth at its SEALSQ subsidiary. The company ...
- Full year 2025 revenue reached CHF 19.3 million, a 62% increase year-over-year, with SEALSQ contributing CHF 18.3 million and growing 66%.
- The company ended 2025 with a transformed balance sheet, holding over CHF 429 million in cash and short-term investments, rising to more than CHF 535 million following a March 2026 capital raise.
- SEALSQ’s commercial pipeline now exceeds $200 million, covering potential revenue opportunities from 2026 through 2029, with over $60 million tied directly to QS7001 and QVault TPM programs.
- +7 more takeaways
Darling Ingredients Inc
Darling Ingredients delivered a sharp Q1 2026 rebound, with Combined Adjusted EBITDA nearly doubling to $407 million, fueled by a $97 million favorable inventory adjustment at Diamond Green Diesel and...
- Combined Adjusted EBITDA surged to $407 million in Q1 2026, nearly doubling from $196 million in Q1 2025, driven by a $97 million favorable lower-of-cost-or-market inventory adjustment at Diamond Green Diesel (DGD) and strong performance in the core ingredients business.
- Core Ingredients EBITDA reached $256 million, up from $190 million year-over-year, with gross margins expanding to 26.1% from 22.6%, reflecting operational excellence, cost reductions, and commercial agility in pivoting to higher-priced markets.
- Diamond Green Diesel (DGD) reported $151 million in EBITDA, or $1.11 per gallon, supported by a constructive Renewable Volume Obligation (RVO) environment and strong renewable diesel margins. DGD is running near full capacity, with Q2 volume guidance at 320 million gallons.
- +9 more takeaways
Quanta Services Q1 2026 Earnings Call - Record Backlog and Upside Guidance Drive Doubles Growth
Quanta Services delivered a robust first quarter, with revenues of $7.9 billion and adjusted EPS of $2.68, driven by a record $48.5 billion backlog and broad-based demand across utility, generation, a...
- Quanta Services reported Q1 2026 revenues of $7.9 billion, net income of $221 million, and adjusted EPS of $2.68, beating expectations and reflecting robust double-digit growth across key segments.
- The company raised its full-year 2026 guidance, now projecting revenues of $34.7 billion to $35.2 billion, adjusted EBITDA of $3.49 billion to $3.65 billion, and adjusted EPS of $13.55 to $14.25, driven by a record $48.5 billion backlog.
- Management announced a $500 million to $700 million investment over the next several years to double power transformer manufacturing capacity, addressing critical supply chain bottlenecks and lead times.
- +12 more takeaways
Norwegian Cruise Line Holdings Q1 2026 Earnings Call - CEO Turnaround and Cost Cuts Amidst Revenue Woes and Geopolitical Headwinds
Norwegian Cruise Line Holdings reported a Q1 2026 that landed in line with expectations, yet the broader 2026 outlook is fraught with structural challenges and external shocks. New CEO John Chidsey, j...
- New CEO John Chidsey, three months into his tenure, is framing the Q1 2026 results as a turning point, openly acknowledging self-inflicted wounds in marketing and revenue management that have left the Norwegian brand behind the booking curve.
- Management is executing an aggressive $125 million annualized SG&A reduction, driven by a streamlined shoreside organization, targeted role adjustments, and a sharp cut in marketing spend to improve capital efficiency.
- Full-year 2026 Net Yield guidance has been lowered to a 3% to 5% decline, with Q3 expected to be significantly weaker due to heavy European exposure and lingering booking curve deficits exacerbated by Middle East geopolitical tensions.
- +7 more takeaways
Krystal Biotech Q1 2026 Earnings Call - VYJUVEK Revenue Hits $116.4M as Pipeline Accelerates Toward Registrational Readouts
Krystal Biotech delivered a quarter defined by disciplined execution and compounding regulatory advantages. VYJUVEK revenue grew 9% sequentially to $116.4 million, buoyed by a resilient U.S. commercia...
- VYJUVEK global net revenue grew 9% sequentially to $116.4 million in Q1 2026, marking the 11th consecutive quarter of positive EPS and 95% gross margin.
- U.S. commercial execution remains strong with over 695 reimbursement approvals and a growing prescriber base of more than 570 unique physicians since launch.
- International launch momentum is building, with Europe and Japan contributing $28.9 million in net revenue and over 140 DEB patients prescribed VYJUVEK.
- +7 more takeaways
Superior Group of Companies Q1 2026 Earnings Call - Execution Wins in Uncertainty
Superior Group of Companies delivered a solid Q1 2026, with revenue up 3% to $141 million and EBITDA rising 37% to $4.8 million, driven by volume gains in Branded Products and Healthcare Apparel, alon...
- Revenue grew 3% year-over-year to $141 million, with EBITDA up 37% to $4.8 million and EPS turning positive at $0.06 versus a $0.05 loss in Q1 2025.
- Branded Products, the largest segment, posted 5% revenue growth and a 210 basis point gross margin expansion, driven by volume gains and favorable customer mix.
- Healthcare Apparel revenue also grew 5%, but gross margins contracted 160 basis points due to growth with lower-margin customers, prompting a strategic review under new leadership.
- +7 more takeaways
Air Products FY2026 Q2 Earnings Call - Helium Disruption and Semiconductor Supercycle Drive Raised Guidance
Air Products delivered a strong second quarter of fiscal 2026, with EPS rising 19% to $3.20 and operating margins expanding to 23.7%. The results were fueled by resilient on-site volumes, particularly...
- EPS grew 19% year-over-year to $3.20, beating the top end of guidance.
- Management raised full-year EPS guidance to $13.00-$13.25, implying 8-10% growth.
- Operating margin expanded 200 basis points to 23.7% driven by volume, productivity, and currency.
- +7 more takeaways
L.B. Foster Q1 2026 Earnings Call - Rail Recovery and Margin Expansion Drive Profitability Surge
L.B. Foster delivered a robust start to 2026, with Q1 sales jumping 23.9% year-over-year to $121.1 million, fueled by a sharp rebound in its Rail segment. The company's gross margins expanded 60 basis...
- Q1 sales surged 23.9% to $121.1 million, with Rail group sales jumping 38.4% year-over-year as customer demand normalized after last year's government funding pauses.
- EBITDA more than tripled to $5.2 million, up 183% from last year, driven by strong sales growth and broad-based margin expansion across both segments.
- Gross margins improved 60 basis points to 21.2%, while SG&A as a percentage of sales declined 240 basis points to 19%, highlighting effective operating leverage.
- +9 more takeaways
Twist Bioscience Q2 2026 Earnings Call - AI-Driven Discovery Fuels 19% Revenue Growth and Margin Expansion
Twist Bioscience delivered a strong second quarter, with revenue growing 19% year-over-year to $110.7 million, marking its 13th consecutive quarter of sequential growth. The company’s semiconductor-ba...
- Revenue grew 19.3% year-over-year to $110.7 million, marking the 13th consecutive quarter of sequential growth.
- Gross margin expanded to 51.6%, up 200 basis points year-over-year, driven by strong revenue growth and operational efficiency.
- DNA synthesis and protein solutions revenue increased 28% year-over-year to $53.3 million, fueled by AI-enabled drug discovery.
- +7 more takeaways